A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation

Exclusion Criteria

• •Known additional malignancy that is progressing or requires active treatment.
• •Central nervous system (CNS) metastases requiring treatment and/or leptomeningeal disease.
• •Part 2 only: Prior treatment with an approved or investigational agent targeting KRASG12C.
• •Toxicity from prior therapy that has not recovered to protocol-defined limits.
• •Received thoracic radiation of \> 30 Gy within 6 months of the first dose of study treatment.
• •Participation in another interventional clinical study.
• •History or evidence of interstitial lung disease, including noninfectious pneumonitis.
• •Presence of gastrointestinal condition that may affect drug absorption.
• •Active autoimmune disease requiring systemic treatment, including corticosteroids exceeding a daily dose of 10 mg of prednisone or equivalent.
• •Diagnosis of immunodeficiency or receiving chronic systemic steroid therapy exceeding a daily dose of 10 mg of prednisone or equivalent.
• •Active infection requiring systemic therapy.
• •History of organ transplantation, including allogeneic stem cell transplantation.
• •Receipt of systemic antibiotics within 28 days of the first dose of study treatment.
• •Probiotic usage is prohibited during screening and throughout the study treatment period.
• •Received a live vaccine within 28 days of the planned start of study drug.
• •Laboratory values outside the Protocol-defined ranges.